Three-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis. [electronic resource]
Producer: 20030718Description: 743-9 p. digitalISSN:- 1462-0324
- Aged
- Back Pain -- drug therapy
- Bone Density -- drug effects
- Calcaneus -- physiopathology
- Diphosphonates -- administration & dosage
- Drug Administration Schedule
- Female
- Femur Neck -- physiopathology
- Glucocorticoids -- adverse effects
- Humans
- Hydroxycholecalciferols -- therapeutic use
- Ibandronic Acid
- Injections, Intravenous
- Lumbar Vertebrae -- physiopathology
- Male
- Middle Aged
- Osteoporosis -- chemically induced
- Prospective Studies
- Spinal Fractures -- prevention & control
No physical items for this record
Publication Type: Clinical Trial; Controlled Clinical Trial; Journal Article
There are no comments on this title.
Log in to your account to post a comment.